Capital Asset Advisory Services’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$256K Sell
1,697
-358
-17% -$54.9K 0.01% 257
2025
Q4
$292K Buy
2,055
+85
+4% +$11.1K 0.01% 237
2025
Q3
$253K Sell
1,970
-222
-10% -$27.1K 0.01% 250
2025
Q2
$270K Sell
2,192
-292
-12% -$32.9K 0.01% 233
2025
Q1
$275K Buy
+2,484
New +$264K 0.01% 234
2021
Q1
Sell
-1,088
Closed -$103K 1224
2020
Q4
$103K Buy
+1,088
New +$95.1K 0.02% 455

Other funds holding NVS

Capital Asset Advisory Services's NVS Position: Q1 2026 in Review

Capital Asset Advisory Services reduced its Novartis (NVS) stake by 17% in Q1 2026, selling an estimated $54.9K and leaving 1,697 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #257.

Capital Asset Advisory Services first reported a position in NVS in Q4 2020 and has held it in 6 quarters since. The position peaked at $292K in Q4 2025. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Capital Asset Advisory Services held 1,697 shares of Novartis worth $256K as of Q1 2026.
  • Capital Asset Advisory Services sold 358 Novartis shares in Q1 2026, an estimated $54.9K.
  • Novartis made up 0.01% of Capital Asset Advisory Services's portfolio in Q1 2026, its #257 holding.
  • Capital Asset Advisory Services first reported a position in Novartis in Q4 2020 and has held it in 6 quarters since.
  • Capital Asset Advisory Services's Novartis position peaked at $292K in Q4 2025.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.